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1. Introduction  
Anaphylactic shock is an extreme and life-threatening allergic reaction that requires 
immediate action to prevent death from airway and blood pressure collapse. The acute 
management comprises the use of epinephrine (adrenaline), the first-line medication of 
choice, and H1-antihistaminic drugs in doses that will depend on the severity of symptoms, 
in order to preserve the airway function and maintain the blood pressure and oxygenation 
at acceptable levels (Kemp & Lockey, 2002). On the other hand, long-term management 
comprises identification of precipitants (e.g.: Medications, foods, latex, insect venom) and 
their avoidance, and also immunotherapy.  
One of the main mediators that are released and associated the many anaphylactic 
symptoms is histamine. H1-antihistamines are commonly used to relieve anaphylactic 
cutaneous symptoms such as itching, flushing, and urticaria, but play little role in the relief 
of bronchospasm or gastrointestinal symptoms, and fail to relieve upper airway edema or 
hypotension. Moreover, in usual doses, antihistamines alone do not prevent the explosive 
release of histamine and other mediators of inflammation from mast cells and basophils that 
culminate in the anaphylactic shock.  
Since bronchospasm, hypotension and edema are not reversed immediately with 
antihistamines, a rapid administration of epinephrine is required to revert these symptoms. It 
has potent life-saving ǃ-1 adrenergic vasoconstrictor effects on the small arterioles and 
precapillary sphincters leading to decreased mucosal edema, thereby preventing and relieving 
upper airway obstruction, and also to increased blood pressure, thereby preventing and 
relieving shock. (Kemp et al, 2008). Its strong effect on ǃ-1 adrenergic receptors activation lead 
to increased rate and force of cardiac contractions, while activation of ǃ-2 adrenergic receptors 
leads to increased bronchodilation and decreased release of histamine, tryptase, and other 
mediators of inflammation from mast cells and basophils (T.C. Westfall & D.P. Westfall, 2006). 
The adverse effects of epinephrine therapy involve pallor, headache (ǃ -1 adrenergic 
receptors), palpitations (ǃ-1 adrenergic receptors), tremor, vasodilation, increased release of 
mediators (ǃ-2 adrenergic receptors) and anxiety (central CNS stimulation) that altogether 
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may impose severe risk to patients with cardiac, central nervous system or thyroid diseases. 
On the other hand, glucocorticoids, that down-regulate ǃ-2 while up-regulating ǃ-1 adrenergic 
receptors and are mainstays in the treatment of asthma, have been shown not to reverse 
anaphylaxis symptoms (Simons, 2006). Therefore, in view of the hyper-acute nature of 
anaphylactic shock that limits adequate therapy, prevention is still the most adequate measure. 
Current prevention of anaphylaxis is based on allergen desensitization through specific 
immunotherapy of patients with high-risk of type I hypersensitivity reactions that involve 
immunoglobulin E (IgE)–mediated release of histamine and other mediators. The 
immunotherapy comprises the administration of increased doses of low-concentrated 
specific allergen solution that induce peripheral tolerance associated with differentiation of 
IL-10 and TGF-ǃ - producing CD4+CD25+ regulatory T cells (Francis et al , 2003; Jutel et al, 
2003). The efficacy of immunotherapy is also associated with an increase of antigen-specific 
IgG antibodies that block IgE effects on mast cells and basophils (Akdis & Blaser, 2000). 
Table 1 summarizes the current measures available to treat and prevent anaphylactic shock: 
 
DRUG 
PHASE OF 
MANAGEMENT 
EFFECTS 
EPINEFRINE Acute 
Vasoconstriction, increased peripheral 
vascular resistance, increased blood 
pressure and relief of hypotension and 
shock; decreased mucosal edema and 
relief of upper airway obstruction and 
angioedema (effects through ǃ-1 
adrenergic receptors). Bronchodilation, 
decreased release of mediators (effects 
through ǃ-2 adrenergic receptors). 
H1-ANTIHISTAMINES Acute 
Relief of itching, flushing, urticaria, 
bronchospasm and gastrointestinal 
symptoms. 
β2-ADRENERGIC 
AGONIST 
Acute 
Reversion of bronchospasm by relaxing 
of airway smooth muscle and reduction 
of asphyxia. 
GLUCOCORTICOIDS Acute 
Inhibition of cytokine and arachidonic 
acid derivates production. 
IMMUNOTHERAPY Long-term 
Induction of antigen-specific tolerance 
and increase of blockers antigen-specific 
IgG antibodies production. 
Table 1. Summary of management of anaphylactic shock 
2. Plants as sources of anti-allergic substances 
Over the years, ethnobotanical studies allowed the association of plants with a diversity of 
biological activities and the discovery of new pharmaceutical drugs (Farnsworth et al., 
1994). In the period 1981 to 2006, 52% of the small molecules discovered and in the 
development process were natural products or had their origins in natural products 
(Newman et al., 2007). 
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There have been many reports on the anti-allergic effects of some plants and natural 
compounds (Table 2).  
 
SPECIES EXTRACT 
EXPERIMENTAL 
MODEL 
EFFECT REFERENCE 
Ailanthus 
altissima 
Swingle Rat 
Inhibits production of 
histamine, TNF, IL-6, and 
IL-8, and nuclear NF-
B/Rel A 
Kang et al., 2010 
 
Albizzia 
lebbeck 
Bark aqueous 
extract 
Guinea pig 
Inhibits ileum contraction 
and bronchospasm 
Barua et al.,1997 
Baliospermu
m montanum 
Leaf 
chloroform and 
ethanol 
extracts 
Rat 
Inhibits mast cell 
degranulation 
Venkatesh et al., 
2010 
Calotropis 
gigantea 
Methanol 
extract 
Rat Inhibits paw edema 
Ghaisas et al., 
2011 
 
Camellia 
japonica 
 
Leaf extract. 
(quercetin and 
eugenol) 
Rat 
Inhibits Src-family kinase 
and degranulation in mast 
cells, and passive 
cutaneous anaphylaxis. 
Lee et al., 2008 
Crinum 
glaucum 
Aqueous 
extract 
Guinea pig Inhibits ileum contractions
Okpo and 
Adeyemi, 2002 
Euphorbia 
hirta 
Ethanol extract Rat and mouse 
Inhibits paw edema, 
passive cutaneous and 
systemic anaphylaxis, 
TNF-ǂ and IL-6. 
Youssouf et 
al.,2007 
Garcinia 
brasiliensis 
7-
epiclusianone 
Guinea pig 
Inhibits allergen-evoked 
intestinal spasm 
Neves et al., 2007 
Impatiens 
balsamina 
Petal ethanol 
extract 
(flavonols and 
naphthoquinon
es) 
Mouse 
 
Prevents blood pressure 
fall and 
fatal anaphylactic shock 
Ishiguro et 
al.,1997; 
Fukumoto et 
al.,1996 
Impatiens 
textori 
Flower ethanol 
extract 
(apigenin, and 
luteolin) 
Mouse 
Inhibits scratching 
behavior and blood 
pressure decrease. 
Ueda et al., 2005 
Kalanchoe 
pinnata 
Aqueous 
extract 
(quercitrin) 
Mouse 
Inhibits bronchospasm, 
fatal anaphylactic shock, 
IgE, eosinophilia, IL-5, IL-
10, IL-13 and TNF-ǂ, and 
histamine release. 
Cruz et al, 2011, 
Cruz et al., 2008 
 
Macrocystis 
pyrifera 
seaweed 
Alginic acid Rat 
Inhibits histamine release, 
IL-1ǃ and TNF-ǂ, but not 
IL-6 or IL-8 production. 
Jeong et al., 2006 
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SPECIES EXTRACT 
EXPERIMENTAL 
MODEL 
EFFECT REFERENCE 
Matricaria 
recutita 
Methanol 
extract 
Rat 
Reduces compound 48/80 
induced anaphylaxis and 
histamine release 
Chandrashekhar 
et al., 2011 
Oryza sativa 
Methanol 
extract 
Rat Reduces histamine release Kim et al., 1999 
Picrorhiza 
kurroa 
Root and 
rhizome 
glycoside 
fraction 
Guinea pig, mouse 
and rat. 
Inhibits passive cutaneous 
anaphylaxis, ileum 
contraction but not 
bronchospasm induced by 
histamine. 
Baruah et al., 
1998 
Porcirus 
trifoliata 
Aqueous 
extract 
Rat Inhibits histamine release Lee et al., 1996 
Prunus 
mahaleb 
Ethanol extract
(oleic and 
linoleic acids) 
Guinea pigs 
Ovalbumin-induced 
bronchospasm 
Shams et al., 2007 
Rhus 
javanica 
Gall aqueous 
extract 
Rat and mouse 
Decrease histamine release, 
TNF-ǂ and IL-6 secretion. Kim et al., 2005 
Table 2. Anti-anaphylactic natural products 
Chamomile (Matricaria recutita, Asteraceae) is one of the medicinal plants whose methanol 
extract containing flavonoids, tannins, terpenoids and coumarines has reported properties 
against compound 48/80 induced anaphylaxis in rats (Chandrashekhar et al., 2011). Not 
only plants but also seaweeds containing alginic acid (Jeong et al., 2006) and honeybees-
produced propolis have been marketed for their anticipated anti-allergic effects (revised by 
Sforcin, 2007). Propolis consists of approximately 300 plant-derived compounds including 
flavonoids, phenolic acids, cinnamic acid derivatives, terpenoids, cellulose and amino acids. 
It has demonstrated protection against OVA-sensitized airway inflammatory reaction 
associated with inihibition of mast cell degranulation, and chrysin and kaempferol present 
in the ethanol extract appears to be the main anti-allergic compounds (Nakamura et al., 
2010). Since 2005, there have been a number of double-blind, placebo-controlled clinical 
studies in China investigating the efficacy and safety of Chinese herbal products. The major 
findings of four promising herbal remedies, comprising at least three plant species, were 
revised by Li and Brown (2009).  
Most of the plant products that fight inflammation belong to the chemical groups of 
alkaloids, coumarins, polyphenols, terpenoids and flavonoids. In particular, flavonoids such 
as quercetin, luteolin, fisetin and apigenin have been described with potent 
immunomodulatory properties. Studies on structure-activity relationship of 45 flavonoids 
showed that oberall they were more potent in inhibiting the production of IL-4 which is 
largely associated with allergic reactions (Revised by Kawai et al. 2007). Comalada et al. 
(2006) studied the structure–activity relationship for several flavonoids using primary bone 
marrow-derived mouse macrophages. They observed that some flavonoids inhibit TNF-ǂ 
production as well as iNOS expression and nitric oxide (NO) production in LPS-activated 
macrophages, an effect that has been associated with the inhibition of the NF-B pathway. 
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Suppression of of NF-B nuclear factor activation by Ailanthus altissima swingle has also 
been associated with the reduced production of TNF-ǂ, IL-6, and IL-8 pro-inflammatory 
cytokines and reduced histamine release during induced anaphylaxis (Kang et al., 2010). 
Flavonoids are known to have potent antiallergic activity (Kawai et al, 2007). For instance, 
luteolin and quercetin flavonoids (Figure 1) are potent inducers of the anti-inflammatory 
cytokine IL-10. Structure–activity relationship showed that four hydroxylations at positions 
5, 7, 30 and 40, together with the double bond at C2–C3 and the position of the B ring at 2, 
seem to be necessary for the highest anti-inflammatory effect.  
 
 
Fig. 1. Chemical structures of quercetin and luteolin flavonoids. 
Due to the problematic curative therapeutics, preventive therapy may be an alternative 
life-saving therapy in highly allergic individuals prone to anaphylactic shock. It depends 
primarily on optimal management of risk factors, avoidance of allergen and other 
anaphylactic sensitizers (food, insect stings, plants and drugs), and immunomodulation. 
Since induced immunotolerance therapy involving the administration of increasing doses 
of a specific allergen has had limited success, and currently available immunosuppressive 
drugs are not safe enough to be continuously administered as a prophylactic measure, 
new anti-anaphylactic substances are highly needed in the market. In view of the 
enormous diversity of chemicals produced, medicinal plants are particularly interesting 
for the discovery of new anti-allergic agents as the safety of continuous consumption (e.g. 
herbal infusions) is popularly testified. This is the case of the plant Kalanchoe pinnata, 
whose potential use as source of anti-anaphylactic substances is described below in more 
detail.  
3. The Kalanchoe pinnata example 
Kalanchoe pinnata (Kp, syn Bryophyllum pinnatum Kentz., Bryophyllum calycinum Salisb., 
Crassulaceae) (Figure 2), is widely used in folk medicine in the form of infusions, juices and 
compresses to treat rheumatoid arthritis, gastric ulcer and in skin disorders (Lucas and 
Machado, 1946; Lorenzi and Abreu-Matos, 2008). It is native of Madagascar, Kp is now 
found in several countries such as India, China, and Brazil (Allorge-Boiteau, 1996).  
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Fig. 2. Kalanchoe pinnata (Crassulaceae) : Leaves and Inflorescences 
Antiparasitic (anti-leishmania), antibacterial, hepatoprotective and immunomodulatory 
activities have been described for Kp leaf extracts (Da Silva et al. 1995; Akinpelu, 2000; 
Muñoz et al. 2000; Yadav and Dixit, 2003; Rossi-Bergmann et al. 1994; Almeida et al., 2000). 
Exploratory toxicological studies in mice and humans have indicated absence of chronic and 
acute oral toxicity (Torres-Santos et al., 2003, Sousa et al., 2005). The clinical safety of Kp was 
also suggested during a study in 67 pregnant women (25 to 35 weeks of gestation) and their 
neonates (Plangger et al., 2006), corroborating its popular acceptance and pharmaceutical 
potential. 
Kp contains substances belonging to different chemical classes, including: terpenes 
(Siddiqui et al. 1989; Gaind et al., 1972), bufadienolidos (Yamagishi et al., 1989; Supratman 
et al., 2001) and flavonoids (Gaind and Gupta, 1971; Ichikawa, 1986; Muzitano et al., 
2006a, 2006b and 2009). Kp flavonoids are significantly more abundant when the leaves 
are collected during the summer (Muzitano et al., 2011). Quercitrin (quercetin 3-O--L-
rhamnopyranoside), kaempferol 3-O--L-arabinopyranosyl (12)--L-rhamnopyranoside 
(kapinnatoside), quercetin 3-O--L-arabinopyranosyl (12)--L-rhamnopyranoside and 
4’,5-dihydroxy-3’,8-dimethoxyflavone 7-O--D-glucopyranoside were isolated from a 
bioactive flavonoid fraction obtained from a Kp aqueous extract (Muzitano et al., 2006a, 
2006b and 2009).  
3.1 The anti-anaphylactic effect of the aqueous extract of Kalanchoe pinnata 
The anti-anaphylactic activity of the aqueous extract of Kp leaves given orally to ovalbumin 
(OVA)-sensitized mice indicated the potent immunomodulatory action, preferentially 
inhibiting Th2-type immune responses known to be committed with enhanced susceptibility 
to cutaneous leishmaniasis and to allergies (Rossi-Bergmann et al, 1994; Da Silva et al 1999, 
Cruz et al 2008, Gomes et al 2009). Despite the early reports on the antihistaminic activity of 
Kp using the experimental models of isolated guinea pig ileum contraction and 
vasodilatation in rats (Nassis et al, 1992); its fatty acid associated suppressive activity on T 
cells (Rossi-Bergmann et al, 1994, Almeida et al, 2000).), and its Th2-suppressive and iNOS-
suppressive association with oral protection against cutaneous and visceral leishmaniasis 
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(Da-Silva et al, 1995, Da-Silva et al, 1999, Gomes et al. 2009), only recently the therapeutic 
effect of Kp in allergy was more deeply explored.  
The antianaphylactic activity o Kp was studied using a murine model of OVA-induced 
anaphylactic shock. The intraplantar injection of OVA (2.5 mg/kg) into pre-sensitised mice 
elicited a severe systemic anaphylactic response with death occurring within 15 min-30 min 
of allergen challenge. This extreme allergic reaction was effectively prevented with 400 
mg/Kg of oral Kp during the 14-day sensitization process that maintained alive 100% for 
over 48 h of follow-up. Intraperitoneal injections with 200 mg/kg of Kp every other day 
during the same period of time was also effective, but to a lesser extent (80% of survival), 
similar to observed with 12.5 mg/Kg of i.p. cyclosporin A, an immunosuppressive drug also 
having anti-allergic effect. Interestingly, a single i.p. dose of 200 mg/Kg of Kp 3 h prior to 
OVA challenge was sufficient to protect 60% of the animals, suggesting that not only 
immunosuppression but also modulation of acute events related to shock was critical for 
protection. 
 
 
Fig. 3. Pre-treatment with Kp prevents fatal anaphylactic shock. BALB/c mice (n=5) were 
sensitized with OVA in adjuvant on days 1 and 7, and were challenged with 50 μg of OVA 
on day 14. During the sensitization period, they were treated as follows: i) by the oral route 
(daily doses of 400 mg/Kg of Kp for 14 days), ii) by the intraperitoneal route (7 doses of 200 
mg/Kg of Kp or 12.5 mg/Kg of Cyclosporin in alternate days; or a single dose of 200 
mg/Kg of Kp 3 h before OVA challenge). Controls were left untreated. Upon challenge on 
day 14, death events were monitored for up to 48 h and recorded as shown. The results are 
expressed as the percentage of surviving animals. *p<0.01 compared to untreated group. 
As allergic parameters, the effect of Kp treatment on the number of circulating eosinophils 
and in allergen-specific IgE response was investigated. The OVA-induced enhanced 
eosinophilia was prevented by Kp, especially in animals receiving multiple oral or i.p. 
doses, although a single i.p. dose of Kp could be effective (Figure 4A). The raised production 
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of OVA-specific IgE in sensitized mice was prevented by Kp therapy, particularly in animals 
on the oral regimen (Figure 4B). 
 
    
Fig. 4. Decreased eosinophilia and OVA-specific IgE levels in Kp-treated mice. Mice were 
sensitized and treated with Kp as for Fig. 1. A group of animals was bled 1 h before allergen 
challenge for the percentage of eosinophils in total leukocytes (top) and for individual 
assessment of the serum levels of anti-OVA IgE (bottom). Means±S.D (n=4). *p≤0.05 and 
**p≤0.01 in relation to untreated controls. 
3.2 Quercitrin as an important anti-anaphylactic component of Kalanchoe pinnata 
Like the aqueous extract, the isolated quercitrin flavonoid (Figure 5) was found to to be 
active in mice against cutaneous leishmaniasis caused by Leishmania amazonensis infection 
(Muzitano et al, 2006). Since cutaneous leishmaniasis, like allergy, is a disease driven by 
Th2-type immune responses, quercitrin was tested in the mouse model of OVA-induced 
anaphylactic shock. The animals were treated daily with oral quercitrin during the 14-day 
OVA-sensitization, with a dose 5% of that used with Kp (400 mg/Kg), compatible with its 
content in the aqueous extract. We observed that oral treatment with quercitrin conferred 
resistance to fatal anaphylactic shock in 75% of the animals, as compared with 0% of 
resistance in untreated sensitized animals (Figure 6), suggesting that quercitrin is an 
important anti-anaphylactic component of Kp. 
 
 
Quercitrin: R= O-ǂ-ramnopyranose 
Fig. 5. Chemical structure of quercitrin.  
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To better analyze the modulatory effect on Th2-type T cells, IL-5 and IL-10 cytokines were 
measured in the cell culture supernatants. Treatment of sensitized mice with oral or i.p. Kp 
reduced the capacity of their cells to respond to OVA with IL-5 and IL-10 production (Fig. 
7). The production of TNF-ǂ was also inhibited by Kp treatment, and like IL-10, this effect 
was more pronounced when the i.p. route was used, indicating that cytokines that 
contribute to allergy are down regulated during i.p, and to a lesser extent oral Kp 
treatments. The importance of the TNF-ǂ was confirmed in mice deficient in TNFR1, and 
corroborated with other studies on Ailanthus altissimain and Euphorbia hirta (Table 2). 
  
 
Fig. 6. Pre-treatment with quercitrin partially prevents death due to anaphylactic shock. 
BALB/c mice (n=8) were sensitized as for Fig. 1. During the sensitization period, they were 
daily treated with 20 mg/Kg of quercitrin by the oral route, during 14 days. Controls were 
left untreated. Naive were untreated non-immunized mice. Upon challenge on day 14, death 
events were monitored for up to 90 min and recorded as shown. The results are expressed as 
the percentage of surviving animals. *pb0.01 compared to untreated group. 
The effect of Kp on histamine release by anti-DNP IgE-sensitized mast cells challenged with 
DNP was also investigated, and a significant inhibition of secreted histamine was found in 
cells that were pre-treated with Kp prior to DNP challenge (Fig. 8).  
As mentioned above, cutaneous leishmaniasis and allergy are pathologies associated with 
expanded Th2-type immune responses, and they are benefited from the oral treatment with 
Kp. Although blockade of histamine release may ultimately contribute to the anti-
anaphylactic effect of Kp, it is conceivable that downregulation of Th2-type immune 
responses is more critical for the resistance phenotype. The immunological effects of Kp are 
summarized in Figure 9. 
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Fig. 7. Cytokine production in Kp-treated mice. Lymph nodes were obtained from mice that 
were sensitized and treated with Kp or Cyclosporin A (CyA) as indicated, and the cells 
restimulated in vitro with 1 mg/ml of OVA. After 48 h, the culture supernatants were 
collected for the determination of IL-5, IL-10 and TNF-ǂ levels by ELISA.Means±S.D. (n=5). 
*p≤0.05 and **p≤0.01 in relation to untreated controls. 
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Fig. 8. Prevention of mast cell histamine release by Kp in vitro. Rat peritoneal mast cells 
were sensitized in vitro with anti-DNP IgE and then incubated with 500 μg/ml of Kp for 30 
min prior to the 1-hour challenge with 50 μg/ml of DNP/BSA. Histamine was measured in 
the supernatants by a fluorimetric assay and expressed as the percentage of total histamine 
in cell lysates. Means±S.D (n=4). 
 
 
E: eosinophil, B: B lymphocyte, TH2: TH2 lymphocyte, Mast: mast cell. 
Fig. 9. Anti-anaphylactic mechanisms of Kp. Anaphylactic shock is mediated by 
immunological mechanisms involving the production of Th2 cytokines (IL-4, IL-5, IL-9 and 
IL-13), the production of antigen-specific IgE antibodies, the recruitment and activation of 
eosinophils (through IL-5) and mast cells. The subsequent contact with antigen causes 
crosslinking of IgE molecules that are linked to the surface of mast cells via Fc RI receptor 
and subsequent degranulation. After crosslinking, there is a systemic release of 
inflammatory mediators that responsible for the symptoms and the severity of anaphylaxis. 
Treatment with aqueous extract of Kp inhibits the production of IgE, the production of IL-
10, IL-5 and TNF- degranulation of mast cells and histamine release. 
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The safety of Kp to humans is substantiated by the fact that it is widely consumed in the 
popular medicine, and that a human case of cutaneous leishmaniasis displayed unaltered 
serum toxicological parameters following oral treatment (Torres-Santos et al, 2003). For its 
effectiveness in mice and expected clinical safeness, quercitrin-containing Kp or quercitrin 
alone are potential candidates for clinical tests aiming at a prophylactic therapy for 
hypersensitive people under the risk of anaphylactic shock. 
Anaphylaxis is a life-threatening allergic condition. Promising preventive measures include 
allergen nonspecific and allergen-specific immunotherapy. A range of plant species, 
including Kalanchoe pinnata, contain promising anti-allergic substances. Flavonoids extracted 
from K. pinnata, particularly quercitrin that down regulate Th2-type immune responses and 
also inflammatory reactions primarily induced by TNF-ǂ, that together lead to overt release 
of histamine and other mediators by mast cells and basophils, culminating with 
anaphylactic shock.  
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